The Effect of Caffeine in Elderly Citizens

This study has been completed.
Sponsor:
Information provided by:
Herning Hospital
ClinicalTrials.gov Identifier:
NCT00117520
First received: June 30, 2005
Last updated: July 3, 2006
Last verified: July 2002
  Purpose

The study investigated the effect of caffeine on physical performance in healthy citizens aged over 70 years. The main hypothesis was that 6 mg/kg caffeine would improve cycling endurance at 65% of expected maximal heart rate.


Condition Intervention Phase
Healthy Elderly Citizens
Drug: Caffeine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Effect of Caffeine as Endurance Enhancing Drug in the Elderly

Resource links provided by NLM:


Further study details as provided by Herning Hospital:

Primary Outcome Measures:
  • endurance measured on an ergometer bicycle

Secondary Outcome Measures:
  • postural stability
  • reactiontime
  • isometric endurance (armflexion)
  • walking speed
  • fatigue

Estimated Enrollment: 30
Study Start Date: July 2002
Estimated Study Completion Date: March 2006
Detailed Description:

Caffeine ingestion increases the endurance of young people exercising at 60%-85% of their maximal oxygen uptake, and it also seems to improve endurance as measured by repeated sub-maximal isometric contraction and decreases the rate of perceived exertion during exercise. Although caffeine increases endurance in young people, an increase in endurance may be of greater interest in the elderly as the population of older adults with a physically active lifestyle is growing rapidly or for increasing endurance fitness through an exercise or rehabilitation program. Therefore the main hypothesis was that caffeine would improve cycling endurance at 65% of expected maximal heart rate, and the secondary hypotheses were that caffeine would improve postural stability, reaction and movement times, isometric arm flexion endurance, and walking speed, and would reduce the rate of perceived exertion after 5 minutes of cycling in healthy elderly citizens.

  Eligibility

Ages Eligible for Study:   70 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy elderly individuals aged over 70 years

Exclusion Criteria:

  • Dementia or invalidating psychiatric disease
  • General debility, angina, or other diseases that would render participation in the test program impossible
  • Treatment with beta receptor blocking drugs, calcium-channel blocking drugs, digitalis, or nitroglycerine
  • Acute disease and injury
  • Diabetes
  • Conditions that would contraindicate caffeine ingestion or participation in the test program
  • Treatment with medication that interacts with caffeine
  • Ingestion of caffeine containing drinks and foods 48 hours before each session
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00117520

Locations
Denmark
Surgical Research Department
Herning, Ringkjoebing, Denmark, 7400
Sponsors and Collaborators
Herning Hospital
Investigators
Principal Investigator: Charlotte B Norager, M.D Surgical Research Department, Herning Hospital, DK-7400 Herning
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00117520     History of Changes
Other Study ID Numbers: 2612-1987
Study First Received: June 30, 2005
Last Updated: July 3, 2006
Health Authority: Denmark: National Board of Health

Keywords provided by Herning Hospital:
caffeine, endurance, postural stability, elderly

Additional relevant MeSH terms:
Caffeine
Central Nervous System Stimulants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents

ClinicalTrials.gov processed this record on August 28, 2014